– USA, CA – Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022, bringing the board to six members.
“I am very pleased to welcome Beverly to our board of directors. Beverly’s extensive management and board experience in the medical device industry and proven track record with non-invasive and minimally invasive devices makes her the perfect candidate for our board,” said Board Chairman.
About Beverly Huss
Ms. Huss brings more than 25 years of business operations, management, and corporate governance experience in the medical device industry. Since January 2021, she has served as the CEO of Pagonia Medical, Inc.; a private company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, or traumatic brain injury. In addition, from September 2013 until January 2021, she served as President and CEO of Qool Therapeutics, Inc., a company focused on temperature management therapies. Before joining Qool, Ms. Huss was President and CEO of a start-up medical device company, Vibrynt, Inc. She held multiple senior-level leadership positions at Guidant Corporation, including President, Endovascular Solutions, VP, Global Marketing, Vascular Intervention, and VP of the Stent Business Unit. Ms. Huss currently serves on the board of directors of Pagonia Medical, Accuray, Madorra Inc., Coala-Life, and Ancora Heart, Inc. Her prior board experience includes Artes Medical, Wright Medical Inc., Kalera Medical, Surefire Medical, Ulthera, and Dade Behring, Inc.
Beverly Huss commented, “I am honored to join the Iridex board of directors. I look forward to working with my fellow board members and company management to advance the Company’s unique, laser-based approach to glaucoma treatment.”
Ms. Huss holds a B.S. in metallurgical engineering from the University of Illinois and an M.S. in technology management from Pepperdine University.
About Iridex
Iridex is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used to treat glaucoma and diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally, primarily through independent distributors in more than 100 countries.
For more information: https://www.iridex.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.